Meningitis C vaccine is cost effective

Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales BMJ Volume 324, pp 809-12

The introduction of meningococcal C vaccine in the UK in 1999 has rapidly and substantially reduced the incidence of meningitis in young people and is cost effective, finds a study in this week’s BMJ.

Researchers at the Public Health Laboratory Service in London assessed the cost effectiveness of the vaccination campaign in people aged 0-17 years.

Immediately before the introduction of the vaccine, the burden of meningitis C was considerable, with an estimated 1,137 cases in people aged 0-17 years and at least 72 deaths annually. The vaccination campaign is estimated to have cost between £126m ($180m) and £241m ($343m) and the cost per life year saved is estimated to be £6,259 ($8919).

School based vaccination was more cost effective than routine vaccination of infants because delivery costs are lower and fewer doses are required, conclude the authors.

###

[ | E-mail |

Share ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.